ImmuCell (ICCC) vs Insight Molecular Diagnostics (IMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmuCell (ICCC) has outperformed Insight Molecular Diagnostics (IMDX) over the past year, gaining 50.2% versus a loss of 6.0%. Over five years, ICCC leads with a +4.4% price change compared with -94.9% for IMDX. Insight Molecular Diagnostics is the larger company by market cap ($113.2 million vs $88.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | IMDX |
|---|---|---|
| Share price | $9.69 | $3.46 |
| Market cap | $88.01M | $113.23M |
| 1-day change | -2.81% | +2.37% |
| YTD return | +57.56% | -53.87% |
| 1-year return | +50.23% | -5.98% |
| 5-year return | +4.42% | -94.91% |
| P/E ratio (TTM) | 138.43 | — |
| EPS (TTM) | $0.07 | $-1.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.10 | $8.51 |
| 52-week low | $4.52 | $2.42 |
| Distance from 52-week high | -19.92% | -59.34% |
| Average volume | 23.16K | 234.39K |
| Shares outstanding | 9.08M | 32.72M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICCC has outperformed IMDX by 56.2 percentage points over the past year.
ICCC vs IMDX FAQ
Which is bigger, ImmuCell or Insight Molecular Diagnostics?
Insight Molecular Diagnostics (IMDX) is larger, with a market capitalization of $113.23M compared with $88.01M for ImmuCell (ICCC).
Which stock has performed better over the past year, ICCC or IMDX?
ICCC returned +50.23% over the past 12 months, compared with -5.98% for IMDX (price return, excluding dividends). Past performance does not predict future results.
Are ImmuCell and Insight Molecular Diagnostics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.